Published in Circulation on June 01, 2004
Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med (2007) 2.23
Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci U S A (2007) 1.98
Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension (2010) 1.85
Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab (2011) 1.64
Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension (2005) 1.60
Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol (2011) 1.38
Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep (2010) 1.34
Aldosterone and arterial hypertension. Nat Rev Endocrinol (2009) 1.06
Role of cellular mechanics in the function and life span of vascular endothelium. Pflugers Arch (2011) 0.96
Nigella sativa and Its Protective Role in Oxidative Stress and Hypertension. Evid Based Complement Alternat Med (2013) 0.94
Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol (2013) 0.92
Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension (2016) 0.90
Is the vascular endothelium under the control of aldosterone? Facts and hypothesis. Pflugers Arch (2007) 0.89
Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol (2005) 0.89
Licorice consumption as a cause of posterior reversible encephalopathy syndrome: a case report. Crit Care (2011) 0.88
Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure. Hypertension (2015) 0.88
Is the mineralocorticoid receptor a potential target for stroke prevention? Clin Sci (Lond) (2008) 0.85
The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series). Pulm Circ (2014) 0.84
Role of aldehyde dehydrogenase 2 Glu504lys polymorphism in acute coronary syndrome. J Cell Mol Med (2011) 0.84
Aldosteronism and resistant hypertension. Int J Hypertens (2011) 0.83
Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism. Hypertension (2015) 0.81
Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol (2005) 0.80
Mineralocorticoid receptor antagonists and endothelial function. Curr Opin Investig Drugs (2008) 0.80
Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. Clin Exp Pharmacol Physiol (2013) 0.79
Rapid aldosterone signaling and vascular reactivity: relax or don't do it. J Cardiovasc Pharmacol (2009) 0.79
Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism. Semin Nephrol (2013) 0.78
Cumulative Hypoxemia During Sleep Predicts Vascular Endothelial Dysfunction in Patients With Sleep-Disordered Breathing. Am J Hypertens (2015) 0.76
Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension. Am J Hypertens (2016) 0.75
Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease. Medicine (Baltimore) (2016) 0.75
Asymmetric Dimethylarginin (ADMA) as a Marker of Endothelial Dysfunction in Primary Aldosteronism. Int J Endocrinol Metab (2016) 0.75
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension (2009) 4.26
Pathogenesis of hypertension. Ann Intern Med (2003) 3.18
Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension (2013) 2.74
Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens (2003) 2.54
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) (2011) 2.11
Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov (2002) 1.98
Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest (2013) 1.88
Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension (2010) 1.85
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest (2007) 1.65
Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens (2007) 1.54
Moderate waist circumference and hypertension prevalence: the REGARDS Study. Am J Hypertens (2011) 1.50
Resistant hypertension: incidence, prevalence, and prognosis. Circulation (2012) 1.46
Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens (2016) 1.43
Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc (2013) 1.31
A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR. J Cardiovasc Magn Reson (2009) 1.29
Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension (2004) 1.22
Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med (2010) 1.15
Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension (2007) 1.14
Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich) (2012) 1.10
Resistant hypertension and aldosterone: an update. Can J Cardiol (2012) 1.08
Characterization and treatment of resistant hypertension. Curr Cardiol Rep (2009) 1.07
Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study. Hypertension (2010) 1.01
Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol (2011) 1.01
Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol (2013) 0.99
Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens (2005) 0.99
Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep (2008) 0.97
Resistant hypertension and aldosteronism. Curr Hypertens Rep (2007) 0.96
Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis (2011) 0.94
Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. Cardiol Clin (2010) 0.94
First Brazilian position on resistant hypertension. Arq Bras Cardiol (2012) 0.94
Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. J Hypertens (2003) 0.92
Aldosterone and cardiovascular disease: smoke and fire. Circulation (2006) 0.91
Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens (2012) 0.91
Aldosterone and cardiovascular disease. Curr Probl Cardiol (2009) 0.89
Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag (2013) 0.88
Aldosterone, dietary salt, and renal disease. Hypertension (2006) 0.88
Increased circulating inflammatory endothelial cells in blacks with essential hypertension. Hypertension (2013) 0.87
Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis (2009) 0.86
Hypertensive crisis: forget the numbers. J Hypertens (2012) 0.85
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich) (2011) 0.84
Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control (2013) 0.84
Recent advancements in the treatment of resistant hypertension. Postgrad Med (2012) 0.84
The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Curr Hypertens Rep (2007) 0.83
Aldosteronism and resistant hypertension. Int J Hypertens (2011) 0.83
The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens (2013) 0.83
Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens (2011) 0.83
Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich) (2008) 0.83
The role of aldosterone antagonists in the management of resistant hypertension. Curr Hypertens Rep (2005) 0.83
Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens (2011) 0.80
Associations of C-Reactive Protein to Indices of Vascular Health and the Influence of Serum 25(OH)D Status in Healthy Adults. J Nutr Metab (2012) 0.80
Apparent and true resistant hypertension: why not the same? J Am Soc Hypertens (2013) 0.80
Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opin Pharmacother (2009) 0.78
Treatment of resistant hypertension. J Hypertens (2010) 0.78
Salt and aldosterone: a concert of bad effects. Hypertension (2010) 0.78
Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol (2007) 0.78
Primary aldosteronism: diagnosis and treatment. J Clin Hypertens (Greenwich) (2006) 0.78
Weight gain and hypertension: the chicken-egg question revisited. J Hypertens (2004) 0.78
Resistant hypertension: who and how to evaluate. Curr Opin Cardiol (2009) 0.77
Reduction of blood pressure in patients with treatment-resistant hypertension. Expert Opin Pharmacother (2009) 0.77
Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function. J Cardiovasc Magn Reson (2014) 0.77
Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test (2004) 0.77
2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice? Pol Arch Med Wewn (2008) 0.76
Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension (2009) 0.76
Resistant hypertension: bad and getting worse. Hypertension (2011) 0.76
Serum 25-hydroxyvitamin D and Ethnic Differences in Arterial Stiffness and Endothelial Function. J Clin Med Res (2012) 0.76
Response. Chest (2013) 0.75
Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther (2006) 0.75
Sympathetic-vascular interactions: further evidence in kidney transplantation. J Hypertens (2002) 0.75
Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity. Hypertension (2014) 0.75
Hypertension and orthostatic hypotension in older patients. J Hypertens (2012) 0.75
Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries. J Hypertens (2006) 0.75
Apparent resistant hypertension and medication adherence. Hypertens Res (2010) 0.75
True resistant hypertension: definition and prevalence. J Hypertens (2012) 0.75
Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension? Hypertension (2014) 0.75
OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX. J Hypertens (2016) 0.75
OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN. J Hypertens (2016) 0.75
OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN. J Hypertens (2016) 0.75
Primary aldosteronism: diagnostic and therapeutic considerations. Curr Cardiol Rep (2005) 0.75
Current options for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther (2009) 0.75
Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens (Greenwich) (2004) 0.75
Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens (2017) 0.75
OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX. J Hypertens (2016) 0.75
Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exercise. Workplace Health Saf (2014) 0.75
Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. Curr Hypertens Rep (2005) 0.75